Impact of time from transplant to treatment of patients with refractory cytomegalovirus infection: post hoc analysis of Phase 3 SOLTICE study

被引：0
|
作者：
Chemaly, R.
Avery, R.
Dadwal, S.
Kamar, N.
Maertens, J.
Papanicolaou, G. A.
Witzke, O.
Gu, J.
Auciello, J.
机构：
来源：
SWISS MEDICAL WEEKLY | 2022年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P24
引用
收藏
页码：8S / 8S
页数：1
相关论文
共 50 条
  • [1] Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial.
    Silveira, F.
    Haider, S.
    Kaul, D.
    Witzke, O.
    Gu, J.
    Sundberg, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 931 - 932
  • [2] Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy
    Marcellusi, Andrea
    Bini, Chiara
    Corinti, Simone
    Fioravanti, Laura
    Vedova, Laura Dalla
    Amorosi, Stacey L.
    De Lacey, Tam
    Chowdhury, Emtiyaz
    Mennini, Francesco Saverio
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2023, 24 (01) : 21 - 41
  • [3] Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data
    Rolfo, C.
    Gerber, D. E.
    Kotecha, R.
    Ward, J.
    Akerley, W.
    Naveh, A.
    Shapira, N.
    Leal, T.
    Langer, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S188 - S188
  • [4] Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
    Avery, Robin K.
    Alain, Sophie
    Alexander, Barbara D.
    Blumberg, Emily A.
    Chemaly, Roy F.
    Cordonnier, Catherine
    Duarte, Rafael F.
    Florescu, Diana F.
    Kamar, Nassim
    Kumar, Deepali
    Maertens, Johan
    Marty, Francisco M.
    Papanicolaou, Genovefa A.
    Silveira, Fernanda P.
    Witzke, Oliver
    Wu, Jingyang
    Sundberg, Aimee K.
    Fournier, Martha
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (04) : 690 - 701
  • [5] INDIGO NATURALIS IS EFFECTIVE IN TREATMENT-REFRACTORY PATIENTS WITH ULCERATIVE COLITIS: POST-HOC ANALYSIS FROM INDIGO STUDY
    Naganuma, Makoto
    Sugimoto, Shinya
    Mitsuyama, Keiichi
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Hisamatsu, Tadakazu
    Watanabe, Kenji
    Abe, Takayuki
    Hibi, Toshifumi
    Suzuki, Yasuo
    Kanai, Takanori
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S380
  • [6] Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study
    Naganuma, Makoto
    Sugimoto, Shinya
    Fukuda, Tomohiro
    Mitsuyama, Keiichi
    Kobayashi, Taku
    Yoshimura, Naoki
    Ohi, Hidehisa
    Tanaka, Shinji
    Andoh, Akira
    Ohmiya, Naoki
    Saigusa, Keiichiro
    Yamamoto, Takayuki
    Morohoshi, Yuichi
    Ichikawa, Hitoshi
    Matsuoka, Katsuyoshi
    Hisamatsu, Tadakazu
    Watanabe, Kenji
    Mizuno, Shinta
    Abe, Takayuki
    Suzuki, Yasuo
    Kanai, Takanori
    Naganuma, Makoto
    Sugimoto, Shinya
    Mizuno, Shinta
    Nakazato, Yoshihiro
    Fukuda, Tomohiro
    Teratani, Toshiaki
    Ogata, Haruhiko
    Iwao, Yasushi
    Kanai, Takanori
    Yamasaki, Hiroshi
    Mitsuyama, Keiichi
    Kobayashi, Taku
    Toyonaga, Takahiko
    Nakano, Masaru
    Hibi, Toshifumi
    Yoshimura, Naoki
    Sameshima, Yoichi
    Ohi, Hidehisa
    Hayashi, Ryohei
    Ueno, Yoshitaka
    Tanaka, Shinji
    Bamba, Shigeki
    Andoh, Akira
    Watanabe, Mamoru
    Saigusa, Keiichiro
    Nakazawa, Atsushi
    Morohoshi, Yuichi
    Koike, Yuji
    Imai, Jin
    JOURNAL OF GASTROENTEROLOGY, 2020, 55 (02) : 169 - 180
  • [7] Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study
    Makoto Naganuma
    Shinya Sugimoto
    Tomohiro Fukuda
    Keiichi Mitsuyama
    Taku Kobayashi
    Naoki Yoshimura
    Hidehisa Ohi
    Shinji Tanaka
    Akira Andoh
    Naoki Ohmiya
    Keiichiro Saigusa
    Takayuki Yamamoto
    Yuichi Morohoshi
    Hitoshi Ichikawa
    Katsuyoshi Matsuoka
    Tadakazu Hisamatsu
    Kenji Watanabe
    Shinta Mizuno
    Takayuki Abe
    Yasuo Suzuki
    Takanori Kanai
    Journal of Gastroenterology, 2020, 55 : 169 - 180
  • [8] Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
    Kirkham, Bruce
    Nash, Peter
    Navarra, Sandra
    Quebe-Fehling, Erhard
    Gaillez, Corine
    Sastre, Carlos
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [9] PHASE 3 OPEN-LABEL STUDY OF MARIBAVIR FOR REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS: SUBGROUP ANALYSES BY ORGAN TYPE
    Kamar, Nassim
    Avery, Robin K.
    Blumberg, Emily A.
    Florescu, Diana
    Kumar, Deepali
    Wu, Jingyang
    Sundberg, Aimee
    TRANSPLANT INTERNATIONAL, 2021, 34 : 46 - 46
  • [10] Post Hoc Analysis of a Phase 2/3 Study in Japanese Patients with iTTP Treated with Caplacizumab
    Imada, Kazunori
    Miyakawa, Yoshitaka
    Ichikawa, Satoshi
    Uchiyama, Hitoji
    Ueda, Yasunori
    Hashimoto, Yasuhiro
    Nishimi, Masashi
    Tahara, Sayaka
    Matsumoto, Masanori
    BLOOD, 2023, 142
12345